.Nature Medicine, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint requires incorporation of individuals along with MASLD and size of liver results in cardio-- renal-- metabolic trials, when information propose mechanistically probable perks and professional safety and security-- and also summarizes points to consider for trial design as well as regulative approval.